NCT05923281已完成3 期
A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance-Multicenter, Placebo Controlled, Randomized, Double Blind, Parallel Group Controlled Trial in Patients With Statin Intolerant Hypercholesterolemia-
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 71
- 试验地点
- 22
- 主要终点
- Percent change from baseline in LDL-C (formula F).
研究概览
简要总结
To investigate the efficacy and safety of K-877 Extended Release 0.2 mg/day or 0.4 mg/day for 12 weeks in patients with Statin Intolerant* Hypercholesterolemia,using placebo as a controll.
*Statin Intolerant: Adverse events associated with statin use that cause unacceptable disturbances in the user's daily life, resulting in drug discontinuation or dose reduction.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The person who meet all the following criteria the object to the clinical trial
- •Patients had to be age 18 years or older at written informed consent
- •Patients with statin intolerant hypercholesterolemia
- •Patients who have laboratory records with fasting serum TG <= 150 mg/dL (<=175 mg/dL when not fasting) within 6 months prior to consent.
- •Patients with the fasting serum TG <= 150 mg/dL at screening
- •Patients who have received dietary or exercise guidance from 12 weeks or more prior to Screening
- •Patients who apply any of the following risk category with LDL-C level (Friedewald formula) based on JAS2022 at screening
- •Low risk for primary prevention: LDL-C >=160 mg/dL
- •Intermediate risk for primary prevention: LDL-C >=140 mg/dL
- •High risk for primary prevention: LDL-C>=120 mg/dL
- •Secondary prevention: LDL-C>=120 mg/dL
排除标准
- •The person who meet any of the following criteria will be excluded from the study.
- •Patients who require administration of prohibited drugs during the clinical trial period after written informed consent
- •Patients with type 1 diabetes and uncontrolled diabetes [HbA1c(NGSP) >= 10.0 % at Screening]
- •Patients with uncontrolled thyroid disease
- •Patients with undergoing LDL apheresis
- •Patients with cirrhosis or those with biliary obstruction
- •Patients with familial hypercholesterolemia (homozygotes)
- •Patients with uncontrolled hypertension (SBP >= 160 mmHg or DBP >= 100 mmHg) at Screening
- •Patients with an AST or ALT three times the upper limit at Screening
- •Patients with an CK four times the upper limit at Screening
- •Patients with any of the following criteria within 3 months before obtaining informed consent: myocardial infarction, severe or unstable angina pectoris, coronary angioplasty, coronary artery bypass surgery, stroke, transient ischemic attack, symptomatic carotid artery stenosis, symptomatic peripheral arterial disease, abdominal aortic aneurysm, uncontrolled severe arrhythmia and decompensated heart failure
- •Patients who plan to undergo PCI, CABG, carotid artery or peripheral revascularization
- •Patients with heart failure class III or higher according to NYHA cardiac function classification
- •Patients with malignant tumor or those who are judged to have a high risk of recurrence
- •Patients with a history of myopathy or rhabdomyolysis due to K-877 (pemafibrate)
- •Patients with a history of hypersensitivity due to K-877 (pemafibrate)
- •Patients with a history of serious drug allergies (anaphylactic shock, etc.)
- •Pregnant women, lactating women, women planning to become pregnant or lactating during the study period, or pregnant women*2 who do not use specific contraceptive methods*1
- •Patients who have collected 400 mL or more of whole blood within 16 weeks, or 200 mL or more of whole blood within 4 weeks, or blood samples (plasma and platelet components) within 2 weeks before Screening
- •Patients with alcoholics or drug addicts
- •Patients who participated in other clinical trials of a drug with new active ingredients within 16 weeks or a drug with an approved active ingredients within 12 weeks prior to administration and received an investigational drug other than placebo,or those who will participate in other clinical trials at the same time as the clinical trial
- •Patients who have been determined inappropriate by the investigator, etc
- •1 Acceptable contraceptive methods: oral, implantable/injectable contraceptive hormones, mechanical products [intrauterine devices (IUDs) ,etc] or barrier methods with spermicides (pessaries, condoms, cervical caps, etc)
- •2 Woman of childbearing potential refers to a woman who is physiologically capable of becoming pregnant with a male partner who has not undergone contraception. However, it does not apply if the investigator confirms that any of the following criteria is met.
- •Patients with hysterectomy or tubal ligation before informed consent
- •Post-menopausal women (those who who have passed more than 1 year since their last menstrual period without other medical reasons).
研究组 & 干预措施
Treatment A
Experimental
K-877 0.2 mg/day
干预措施: K-877 0.2 mg/day (once daily) (Drug)
Treatment B
Experimental
K-877 0.4 mg/day
干预措施: K-877 0.4 mg/day (once daily) (Drug)
Control A
Placebo Comparator
Placebo
干预措施: Placebo (once daily) (Drug)
结局指标
主要结局
Percent change from baseline in LDL-C (formula F).
时间窗: 4, 8, and 12 weeks after administration
Percent change = (measured value at each time point - baseline value) / baseline value
次要结局
- Efficacy: % change from baseline in fasting serum LDL-C (mg/dL)(Direct)(4, 8, and 12 week after administration)
- Efficacy: % change from baseline in fasting serum HDL-C (mg/dL)(4, 8, and 12 week after administration)
- Efficacy: % change from baseline in fasting serum non HDL-C (mg/dL)(4, 8, and 12 week after administration)
- Efficacy: % change from baseline in fasting serum TG (mg/dL)(4, 8, and 12 week after administration)
- Efficacy: % change from baseline in fasting serum LDL-C（formula F）/HDL-C(4, 8, and 12 week after administration)
- Efficacy: % change from baseline in fasting serum non HDL-C/HDL-C(4, 8, and 12 week after administration)
研究者
研究点 (22)
Loading locations...
相似试验
已完成
3 期
A Phase III Confirmatory Study of K-877 Extended Release TabletDyslipidemiasNCT04714151Kowa Company, Ltd.356
招募中
3 期
A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients with Hypercholesterolemia and Statin IntoleranceHypercholesterolemiaJPRN-jRCT2051230055Tanigawa Ryohei60
已完成
3 期
A Phase III Long Term Study of K-877 Extended Release TabletDyslipidemiasNCT04716595Kowa Company, Ltd.121
已完成
3 期
A Phase III Confirmatory Study of K-237Covid19NCT05056883Kowa Company, Ltd.1,030
已完成
2 期
Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Compared to K-877-IRDyslipidemiaNCT04447820Kowa Research Institute, Inc.96